Positive News SentimentPositive NewsNASDAQ:OPT Opthea (OPT) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free OPT Stock Alerts $4.11 +0.20 (+5.12%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$3.84▼$4.3850-Day Range$2.54▼$4.1152-Week Range$1.60▼$4.42Volume10,902 shsAverage Volume27,508 shsMarket Capitalization$240.02 millionP/E RatioN/ADividend YieldN/APrice Target$16.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Opthea alerts: Email Address Opthea MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside295.4% Upside$16.25 Price TargetShort InterestHealthy0.23% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.45) to ($2.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.56 out of 5 starsMedical Sector509th out of 938 stocksBiological Products, Except Diagnostic Industry82nd out of 148 stocks 3.5 Analyst's Opinion Consensus RatingOpthea has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.25, Opthea has a forecasted upside of 295.4% from its current price of $4.11.Amount of Analyst CoverageOpthea has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.23% of the outstanding shares of Opthea have been sold short.Short Interest Ratio / Days to CoverOpthea has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Opthea has recently increased by 8.86%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOpthea does not currently pay a dividend.Dividend GrowthOpthea does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OPT. Previous Next 3.8 News and Social Media Coverage News SentimentOpthea has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Opthea this week, compared to 0 articles on an average week.MarketBeat Follows2 people have added Opthea to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Opthea insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.20% of the stock of Opthea is held by insiders.Percentage Held by Institutions55.95% of the stock of Opthea is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Opthea are expected to grow in the coming year, from ($2.45) to ($2.23) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Opthea Stock (NASDAQ:OPT)Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Read More OPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPT Stock News HeadlinesMarch 19, 2024 | globenewswire.comOpthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024March 6, 2024 | msn.comEnd in sight as Opthea looks to be key player in US$10 billion wet AMD marketMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 5, 2024 | globenewswire.comOpthea to Participate in the Leerink Partners Global Biopharma ConferenceFebruary 28, 2024 | globenewswire.comOpthea Reports Half-Year Financial Results and Business UpdatesFebruary 22, 2024 | au.finance.yahoo.comOpthea Limited (OPT)February 20, 2024 | finanznachrichten.deOpthea Limited: Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical AdvisorFebruary 19, 2024 | globenewswire.comOpthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical AdvisorMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.February 14, 2024 | finanznachrichten.deOpthea Limited: Opthea Completes Enrollment in First Pivotal Trial with SoziniberceptFebruary 14, 2024 | finance.yahoo.comOpthea Completes Enrollment in First Pivotal Trial with SoziniberceptFebruary 14, 2024 | globenewswire.comOpthea Completes Enrollment in First Pivotal Trial with SoziniberceptDecember 27, 2023 | msn.comWhy Is Retinal Diseases-Focused Opthea Stock Trading Higher Today?December 27, 2023 | msn.comOpthea to receive $35M commitment and additional $50M fundingDecember 27, 2023 | marketwatch.comOpthea Limited ADRs Rise 31% on Raised FundingDecember 27, 2023 | finance.yahoo.comOpthea to Receive US$35M Commitment and Additional US$50M FundingDecember 16, 2023 | msn.comOpthea Limited - ADR (OPT) Price Target Increased by 7.41% to 6.39December 1, 2023 | finance.yahoo.comOpthea to Present at the FLORetina 2023 CongressNovember 27, 2023 | msn.comOpthea Limited - ADR (OPT) Price Target Increased by 9.06% to 5.95November 9, 2023 | finance.yahoo.comOpthea to Present at the Jefferies 2023 London Healthcare ConferenceOctober 30, 2023 | finance.yahoo.comOpthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) ConferenceOctober 27, 2023 | msn.comOpthea appoints U.S.-based leadership with Fred Guerard as CEOOctober 25, 2023 | finance.yahoo.comOpthea Limited (ASX:OPT) is definitely on the radar of institutional investors who own 38% of the companySeptember 7, 2023 | finance.yahoo.comOpthea to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 23, 2023 | afr.comCarlyle goes all in on biotech Opthea; MST launches $80m capital raiseAugust 1, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Opthea Limited Sponsored ADR (OPT)July 24, 2023 | finance.yahoo.comOpthea to Present at the 2023 Ophthalmology Innovation SummitSee More Headlines Receive OPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opthea and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:OPT CUSIPN/A CIK1815620 Webwww.opthea.com Phone61-3-9826-0399FaxN/AEmployees24Year FoundedN/APrice Target and Rating Average Stock Price Target$16.25 High Stock Price Target$23.00 Low Stock Price Target$12.00 Potential Upside/Downside+295.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio5.25 Quick Ratio5.25 Sales & Book Value Annual Sales$110,000.00 Price / Sales2,182.04 Cash FlowN/A Price / Cash FlowN/A Book Value($0.10) per share Price / Book-41.10Miscellaneous Outstanding Shares58,400,000Free Float56,526,000Market Cap$240.02 million OptionableNot Optionable Beta1.17 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Megan Baldwin M.A.I.C.D. (Age 49)MAICD, Ph.D., Founder, Chief Innovation Officer & Executive Director Comp: $599.73kMs. Judith J. Robertson B.A. (Age 63)M.B.A., Chief Commercial Officer Comp: $588.59kMs. Karen Adams CPA (Age 52)VP of Finance & Company Secretary Comp: $305.14kDr. Frederic Guerard M.S. (Age 51)Pharm.D., Chief Executive Officer Mr. Peter F. Lang M.B.A. (Age 51)Chief Financial Officer Ms. Sarika Gulhar Ph.D.Executive Director of Human ResourcesDr. Michael Gerometta Ph.D. (Age 59)Head of Chemistry, Manufacturing & Controls Development Comp: $129.69kMr. Bruno Gagnon BPHARM (Age 55)M.Sc., Senior Vice President of Global Clinical Operations Dr. Kenneth SallChief Medical OfficerDr. Fang Li Ph.D.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsCompugenNASDAQ:CGENAcumen PharmaceuticalsNASDAQ:ABOSINmune BioNASDAQ:INMBVaxartNASDAQ:VXRTAgenusNASDAQ:AGENView All CompetitorsInstitutional OwnershipOLD Mission Capital LLCBought 12,220 shares on 2/15/2024Ownership: 0.021%View All Institutional Transactions OPT Stock Analysis - Frequently Asked Questions Should I buy or sell Opthea stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Opthea in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OPT shares. View OPT analyst ratings or view top-rated stocks. What is Opthea's stock price target for 2024? 3 Wall Street research analysts have issued 12-month price objectives for Opthea's stock. Their OPT share price targets range from $12.00 to $23.00. On average, they predict the company's share price to reach $16.25 in the next twelve months. This suggests a possible upside of 295.4% from the stock's current price. View analysts price targets for OPT or view top-rated stocks among Wall Street analysts. How have OPT shares performed in 2024? Opthea's stock was trading at $2.95 at the start of the year. Since then, OPT shares have increased by 39.3% and is now trading at $4.11. View the best growth stocks for 2024 here. What guidance has Opthea issued on next quarter's earnings? Opthea updated its FY 2023 earnings guidance on Tuesday, January, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $47.5 million-$47.5 million. When did Opthea IPO? Opthea (OPT) raised $161 million in an IPO on Friday, October 16th 2020. The company issued 9,300,000 shares at a price of $17.26 per share. Citigroup and SVB Leerink served as the underwriters for the IPO and Oppenheimer & Co. and Truist Securities were co-managers. Who are Opthea's major shareholders? Opthea's stock is owned by many different retail and institutional investors. Top institutional shareholders include OLD Mission Capital LLC (0.02%). How do I buy shares of Opthea? Shares of OPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OPT) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.